Top

Cancer Chemotherapy and Pharmacology

Published in:

Open Access 01-12-2018 | Original Article

Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer

Authors: Helena Taflin, Elisabeth Odin, Kristoffer Derwinger, Göran Carlsson, Bengt Gustavsson, Yvonne Wettergren

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Abstract

Purpose

The aim of study was to investigate the relationship between folate concentration and expression of folate-associated genes in tumour, mucosa and plasma of patients with colorectal cancer, after intraoperative administration of bolus leucovorin (LV).

Methods

Eighty patients were randomized into four groups to receive 0, 60, 200, or 500 mg/m² LV, respectively. Tissue and plasma folate concentrations were assessed by LC–MS/MS. Gene expression of ABCC3/MRP3, FPGS, GGH, MTHFD1L, SLC46A1/PCFT, and SLC19A1/RFC-1 was determined using quantitative PCR.

Results

The folate concentration in tumour increased with increasing dosage of LV. Half of the patients treated with 60 mg/m² did not reach a level above the levels of untreated patients. A significant correlation between folate concentration in tumour and mucosa was found in untreated patients, and in the group treated with 60 mg/m² LV. The 5-MTHF/LV ratio correlated negatively with folate concentration in mucosa, whereas a positive correlation was found in tumour of patients who received 200 or 500 mg/m² LV. A positive correlation was found between folate concentration and expression of all genes, except MTHFD1L, in patients who received LV. There was a negative correlation between 5-MTHF concentration in plasma of untreated patients and expression of GGH and SLC46A1/PCFT in tumour.

Conclusions

The results indicate the possibility of using the individual plasma 5-MTHF/LV ratio after LV injection as a surrogate marker for tissue folate concentration. Expression of several folate-associated genes is associated with folate concentration in tissue and plasma and may become useful when predicting response to LV treatment.

Available only for authorised users

Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F (2017) Global patterns and trends in colorectal cancer incidence and mortality. Gut 66(4):683–691. https://doi.org/10.1136/gutjnl-2015-310912 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRef

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Kohne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Osterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235 CrossRefPubMed

Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, Glimelius B (2009) Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 115(20):4679–4687. https://doi.org/10.1002/cncr.24527 CrossRefPubMed

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. https://doi.org/10.1200/jco.2008.20.6771 CrossRefPubMed

Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27(6):872–877. https://doi.org/10.1200/jco.2008.19.5362 CrossRefPubMedPubMedCentral

Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11(10):1879–1887CrossRef

Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD (2014) Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol 11(5):282–298. https://doi.org/10.1038/nrclinonc.2014.51 CrossRefPubMed

Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48(3):381–395CrossRef

10.

Longley DB, Latif T, Boyer J, Allen WL, Maxwell PJ, Johnston PG (2003) The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Sem Oncol 30(3 Suppl 6):3–9CrossRef

11.

Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O’Connell M, Sargent P, Piedbois P (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22(18):3766–3775. https://doi.org/10.1200/jco.2004.03.104 CrossRefPubMed

12.

Houghton JA, Williams LG, de Graaf SS, Cheshire PJ, Rodman JH, Maneval DC, Wainer IW, Jadaud P, Houghton PJ (1990) Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50(12):3493–3502PubMed

13.

Glimelius B, Jakobsen A, Graf W, Berglund A, Gadeberg C, Hansen P, Kjaer M, Brunsgaard N, Sandberg E, Lindberg B, Sellstrom H, Lorentz T, Pahlman L, Gustavsson B (1998) Bolus injection (2–4 min) versus short-term (10–20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Eur J Cancer (Oxf Engl 1990) 34(5):674–678CrossRef

14.

Danenberg PV, Gustavsson B, Johnston P, Lindberg P, Moser R, Odin E, Peters GJ, Petrelli N (2016) Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action. Crit Rev Oncol Hematol 106:118–131. https://doi.org/10.1016/j.critrevonc.2016.08.001 CrossRefPubMed

15.

Priest DG, Schmitz JC, Bunni MA, Stuart RK (1991) Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83(24):1806–1812CrossRef

16.

Lockshin A, Danenberg PV (1981) Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol 30(3):247–257CrossRef

17.

Spears CP, Carlsson G, Muggia FM, Jaresko G, Gustavsson BG (1995) Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy. Cancer Treat Res 78:115–134CrossRef

18.

Taflin H, Wettergren Y, Odin E, Derwinger K (2014) Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages. Cancer Chemother Pharmacol 74(6):1167–1174. https://doi.org/10.1007/s00280-014-2591-9 CrossRefPubMedPubMedCentral

19.

Houghton JA, Williams LG, Loftin SK, Cheshire PJ, Morton CL, Houghton PJ, Dayan A, Jolivet J (1992) Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 30(6):423–432CrossRef

20.

Odin E, Wettergren Y, Carlsson G, Gustavsson B (2013) Determination of reduced folates in tumor and adjacent mucosa of colorectal cancer patients using LC–MS/MS. Biomed Chromatogr BMC 27 (4):487–495. https://doi.org/10.1002/bmc.2816 CrossRefPubMed

21.

Jensen NF, Smith DH, Nygard SB, Romer MU, Nielsen KV, Brunner N (2012) Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 47(3):340–355. https://doi.org/10.3109/00365521.2012.640835 CrossRefPubMed

22.

Lee PP, Schilsky RL (1990) Inhibition of thymidylate synthase by the diastereoisomers of leucovorin. Cancer Chemother Pharmacol 26(4):273–277CrossRef

23.

Schlemmer M, Kuehl M, Schalhorn A, Rauch J, Jauch KW, Hentrich M (2008) Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels. Clin Cancer Res 14(23):7930–7934. https://doi.org/10.1158/1078-0432.ccr-08-0258 CrossRefPubMed

24.

Odin E, Sonden A, Gustavsson B, Carlsson G, Wettergren Y (2015) Expression of folate pathway genes in stage III colorectal cancer correlates with recurrence status following adjuvant bolus 5-FU-based chemotherapy. Mol Med (Camb Mass) 21:597–604. https://doi.org/10.2119/molmed.2014.00192 CrossRef

25.

Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, Veerman AJ, Scheffer GL, Kaspers GJ, Jansen G (2003) The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem Pharmacol 65(5):765–771CrossRef

26.

Lowe KE, Osborne CB, Lin BF, Kim JS, Hsu JC, Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-gamma-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-gamma-glutamate specificity of metabolic cycles of one-carbon metabolism. J Biol Chem 268(29):21665–21673PubMed

27.

Galivan J, Ryan TJ, Chave K, Rhee M, Yao R, Yin D (2000) Glutamyl hydrolase. pharmacological role and enzymatic characterization. Pharmacol Ther 85(3):207–215CrossRef

28.

Kawakami K, Ooyama A, Ruszkiewicz A, Jin M, Watanabe G, Moore J, Oka T, Iacopetta B, Minamoto T (2008) Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype. Br J Cancer 98(9):1555–1561. https://doi.org/10.1038/sj.bjc.6604346 CrossRefPubMedPubMedCentral

29.

Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Lan Li L, Law CT, Tsang FH, Wei LL, Chan CY, Wong CM, Ng IO, Wong CC (2017) Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Investig 127(5):1856–1872. https://doi.org/10.1172/jci90253 CrossRefPubMed

30.

Pike ST, Rajendra R, Artzt K, Appling DR (2010) Mitochondrial C1-tetrahydrofolate synthase (MTHFD1L) supports the flow of mitochondrial one-carbon units into the methyl cycle in embryos. J Biol Chem 285(7):4612–4620. https://doi.org/10.1074/jbc.M109.079855 CrossRefPubMed

31.

Lee D, Wong CC (2017) The folate cycle is a new metabolic weakness of cancer. Mol Cell Oncol 4(6):e1327004. https://doi.org/10.1080/23723556.2017.1327004 CrossRefPubMedPubMedCentral

32.

Kobayashi M, Funayama R, Ohnuma S, Unno M, Nakayama K (2016) Wnt-beta-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer. Cancer Sci 107(12):1776–1784. https://doi.org/10.1111/cas.13097 CrossRefPubMedPubMedCentral

33.

Thakur S, Kaur J (2015) Regulation at multiple levels control the expression of folate transporters in liver cells in conditions of ethanol exposure and folate deficiency. BioFactors 41(4):232–241. https://doi.org/10.1002/biof.1217 CrossRefPubMed

34.

Crott JW, Liu Z, Keyes MK, Choi SW, Jang H, Moyer MP, Mason JB (2008) Moderate folate depletion modulates the expression of selected genes involved in cell cycle, intracellular signaling and folate uptake in human colonic epithelial cell lines. J Nutr Biochem 19(5):328–335. https://doi.org/10.1016/j.jnutbio.2007.05.003 CrossRefPubMed

35.

Thakur S, More D, Rahat B, Khanduja KL, Kaur J (2016) Increased synthesis of folate transporters regulates folate transport in conditions of ethanol exposure and folate deficiency. Mol Cell Biochem 411(1–2):151–160. https://doi.org/10.1007/s11010-015-2577-x CrossRefPubMed

36.

Sadahiro S, Suzuki T, Maeda Y, Tanaka A, Ogoshi K, Kamijo A, Murayama C, Tsukioka S, Sakamoto E, Fukui Y, Oka T (2010) Molecular determinants of folate levels after leucovorin administration in colorectal cancer. Cancer Chemother Pharmacol 65(4):735–742. https://doi.org/10.1007/s00280-009-1079-5 CrossRefPubMed

Title: Relationship between folate concentration and expression of folate-associated genes in tissue and plasma after intraoperative administration of leucovorin in patients with colorectal cancer
Authors: Helena Taflin
Elisabeth Odin
Kristoffer Derwinger
Göran Carlsson
Bengt Gustavsson
Yvonne Wettergren
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3690-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Autophagy therapeutics: preclinical basis and initial clinical studies

A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403

Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition

Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247

Oncogenic roles of serine–threonine kinase receptor-associated protein (STRAP) in osteosarcoma

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer